SSW
PDLI

Smith Shellnut Wilson’s PDL BioPharma, Inc. PDLI Stock Holding History

Smith Shellnut Wilson’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27,196
Closed -$85K – 159
2017
Q2 		$85K Hold
27,196
– – 0.09% 128
2017
Q1 		$62K Hold
27,196
– – 0.06% 119
2016
Q4 		$58K Buy
+27,196
New +$75.9K 0.06% 126

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Smith Shellnut Wilson's PDLI Position: Q3 2017 in Review

Smith Shellnut Wilson sold out of PDL BioPharma, Inc. (PDLI) in Q3 2017, closing a stake of 27,196 shares — an estimated $85K sold.

Smith Shellnut Wilson first reported a position in PDLI in Q4 2016 and held it in 3 quarters. The position peaked at $85K in Q2 2017. 186 funds tracked by Wall St. Rank hold PDLI as of Q3 2017.

  • Smith Shellnut Wilson reported no remaining PDL BioPharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Smith Shellnut Wilson sold 27,196 PDL BioPharma, Inc. shares in Q3 2017, an estimated $85K.
  • Smith Shellnut Wilson first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 3 quarters.
  • Smith Shellnut Wilson's PDL BioPharma, Inc. position peaked at $85K in Q2 2017.
  • 186 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2017.

Based on Smith Shellnut Wilson's 13F filing for Q3 2017, filed 17 Nov 2017.